Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Mono-immunotherapy and combination therapy with immune checkpoint inhibitors (ICIs) and multitargeted tyrosine kinase inhibitors (TKIs) or anti-vascular endothelial gro...

Full description

Bibliographic Details
Main Authors: Xuenan Peng, Caifeng Gong, Wen Zhang, Aiping Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
immunotherapy
combination therapy
biomarker
tumor immune microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1091088/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1091088/full

Similar Items